ES-SCLC vs. LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
Panelists discuss how distinguishing between limited-stage and extensive-stage small cell lung cancer is essential for guiding treatment strategies, accurately staging disease, and setting appropriate expectations for prognosis and therapeutic outcomes.
EP: 1.ES-SCLC vs. LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis
EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC
EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management
EP: 4.Clinical Trials: Novel Approaches in Second-Line ES-SCLC
Summary for Physicians:
The distinction between extensive-stage small cell lung cancer (ES-SCLC) and limited-stage SCLC (LS-SCLC) is critical in understanding differences in disease burden and prognosis.
- ES-SCLC involves disease that has spread beyond a single hemithorax and is not suitable for inclusion within a single, tolerable radiation field. It often includes distant metastases, such as to the liver, brain, or bones. This stage is associated with a higher tumor burden and a poorer prognosis, with median overall survival typically around 8–13 months, even with systemic therapy.
- LS-SCLC is confined to one hemithorax and regional lymph nodes and can be encompassed within a single radiation field. It generally presents with a lower tumor burden and has a relatively better prognosis, with median survival ranging from 15–20 months. A subset of patients may achieve long-term survival with curative-intent chemoradiation.
Understanding this distinction is essential for accurate staging, therapeutic decision-making, and setting realistic expectations for outcomes.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
